Answer
Polatuzumab vedotin (Polivy) may harm the foetus based on its mechanism of action and nonclinical studies, so it is not recommended during pregnancy unless the potential maternal benefit outweighs the potential foetal risk.
Sources for this answer
- Polivy 30 mg and 140 mg powder for concentrate for solution for infusionRoche Products Limited · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 8Document updated
Sources checked